Market-Moving News for June 17th
$BBY
$QTTB
$ZYME
Consumer Electronics/Video Chains
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/1/2024 | $12.00 | Overweight → Equal Weight | Wells Fargo | |
| 10/24/2024 | $90.00 | Strong Buy | Raymond James | |
| 9/11/2024 | $95.00 | Overweight | Wells Fargo | |
| 8/30/2024 | $95.00 → $115.00 | Outperform | Telsey Advisory Group | |
| 6/17/2024 | $100.00 | Buy | Guggenheim | |
| 6/17/2024 | $85.00 → $106.00 | Neutral → Buy | UBS | |
| 6/3/2024 | $67.00 → $100.00 | Sell → Buy | Citigroup | |
| 5/23/2024 | $95.00 | Outperform → Market Perform | Telsey Advisory Group |
10-Q - Zymeworks Inc. (0001937653) (Filer)
8-K - Zymeworks Inc. (0001937653) (Filer)
DEFA14A - Zymeworks Inc. (0001937653) (Filer)
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotec
Collaboration Aims to Drive Sustainability and Inspire the Next Generation of Innovators NEW YORK, April 8, 2024 /PRNewswire/ -- In an exciting new activation, Microsoft, Junk Kouture, and Best Buy have joined forces in driving eco-conscious habits, responsibly recycling old electronics, and a shared commitment to sustainability. The trio are amplifying and empowering the voices of New York's young creatives, offering them a platform to inspire nationwide recycling efforts, drive change in support of a brighter future, powered by the versatility of the Microsoft Surface Pro 9. The quest begins with high school students participating in the Junk Kouture program,
Wells Fargo downgraded Zymeworks from Overweight to Equal Weight and set a new price target of $12.00
Raymond James initiated coverage of Q32 Bio with a rating of Strong Buy and set a new price target of $90.00
Wells Fargo initiated coverage of Q32 Bio with a rating of Overweight and set a new price target of $95.00
First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conferenceOur partner Jazz Pharmaceuticals presented new and updated clinical data at ESMO 2024 on zanidatamab highlighting its potential for the treatment of multiple HER2-positive (HER+) indicationsZymeworks to host in-person and virtual R&D day in New York City on December 12, 2024The Company has completed the initial $30 million of its Share Repurchase Program for 2,545,402 shares at an average price per share of $11.79 as of October 31, 2024Reported $374.9 million in cash resources as of September 30, 2024, which
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: UBS Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.Stifel 2024 Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.Jefferies London
Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in 2H in 2025 VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR)
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
SC 13D/A - BEST BUY CO INC (0000764478) (Subject)
SC 13G/A - BEST BUY CO INC (0000764478) (Subject)
First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conferenceOur partner Jazz Pharmaceuticals presented new and updated clinical data at ESMO 2024 on zanidatamab highlighting its potential for the treatment of multiple HER2-positive (HER+) indicationsZymeworks to host in-person and virtual R&D day in New York City on December 12, 2024The Company has completed the initial $30 million of its Share Repurchase Program for 2,545,402 shares at an average price per share of $11.79 as of October 31, 2024Reported $374.9 million in cash resources as of September 30, 2024, which
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https:/
The Board of Directors of Best Buy Co., Inc. (NYSE:BBY) has authorized the payment of a regular quarterly cash dividend of $0.94 per common share. The quarterly dividend is payable on October 10, 2024, to shareholders of record as of the close of business on September 19, 2024. The company had 215,052,984 shares of common stock issued and outstanding as of August 3, 2024. View source version on businesswire.com: https://www.businesswire.com/news/home/20240829377236/en/
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - BEST BUY CO INC (0000764478) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s
The Nasdaq 100 closed higher by around 300 points during Monday's session. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Best Buy The Trade: Best Buy Co., Inc. (NYSE:BBY) Richard M Schulze sold a total of 1,600,000 shares at an ave
Today, we're excited to share some changes that are coming - to our brand and the personalized experiences we're creating for our customers. We recently rolled out a host of new features on the Best Buy® app designed to give our customers a personalized shopping experience that's as unique as they are. This includes a new personalized home page, a Discover tab where customers can explore new tech, a Shop with Videos experience with personalized video content, personalized push notifications, a new Digital Wallet payment and rewards experience and much more. And just in time for the back-to-school season, we're helping customers find the right tech at the right price point. Customers can n
